Successful treatment of cutaneous Langerhans cell histiocytosis with low-dose methotrexate.

Steen, Astrid; Steen, Kay H.; Bauer, R.; Bieber, Thomas

doi:10.1046/j.1365-2133.2001.04298.x

Cited by 70 publications

(33 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…9 Treatment options for patients with singlesystem cutaneous LCH include topical nitrogen mustard, topical corticosteroids, and oral methotrexate. [15][16][17] Although smoking cessation is the cornerstone of treatment for pulmonary LCH, case reports have described disease improvement following therapy with cladribine. 18,19 Patients with single-system LCH have an excellent prognosis with more than 80% remaining disease free after initial therapy.…”

mentioning

confidence: 99%

Langerhans Cell Histiocytosis: A Clinicopathologic Review and Molecular Pathogenetic Update

Harmon¹,

Brown

2015

Archives of Pathology &Amp; Laboratory Medicine

103

View full text Add to dashboard Cite

Langerhans cell histiocytosis (LCH) comprises a wide spectrum of clinical disorders that have in common a proliferation of Langerhans-type cells with characteristic morphologic, immunophenotypic, and ultrastructural features. In part because of the diverse clinical manifestations of LCH, there has long been controversy over whether LCH is best considered a reactive process or a neoplasm. Herein, we discuss the clinical and pathologic features of LCH, including recent advances in the understanding of the molecular pathogenesis of this disease that support its categorization as a neoplasm. We also review the implications that these recently described molecular characteristics may have on risk stratification and treatment of LCH.

show abstract

mentioning

confidence: 99%

Langerhans Cell Histiocytosis: A Clinicopathologic Review and Molecular Pathogenetic Update

Harmon¹,

Brown

2015

Archives of Pathology &Amp; Laboratory Medicine

103

View full text Add to dashboard Cite

show abstract

“…17–19 Low-dose methotrexate (20 mg weekly) successfully treated multiresistant cutaneous LCH. 20,21 In some patients with multiresistant cutaneous LCH, subcutaneous interferon- α2b achieved long remission periods. 15 Oral thalidomide (N-phtalimidoglutarimide, 200 mg/d) was effective for mucocutaneous LCH after four weeks of treatment with total clearing after three months.…”

Section: Discussionmentioning

confidence: 99%

Photodynamic therapy for multi-resistant cutaneous Langerhans cell histiocytosis

et al. 2010

View full text Add to dashboard Cite

Langerhans cell histiocytosis is a rare group of proliferative disorders. Beside cutaneous involvement, other internal organs can be affected. The treatment of cutaneous lesions is difficult and relies on topical corticosteroids, carmustine, nitrogen mustard, and photochemotherapy. Systemic steroids and vinblastine are used for recalcitrant skin lesions. However, some cases fail to respond. An 18-month old boy presented a CD1a+, S100a+ Langerhans cell histocytosis with cutaneous and severe scalp involvement. Topical corticosteroids and nitrogen mustard failed to improve the skin lesions. Systemic corticosteroids and vinblastine improved the truncal involvement but had no effect on the scalp lesions. Methylaminolevulinate (MAL) based photodynamic therapy (PDT) resulted in a significant regression of the scalp lesions. Control histology revealed an almost complete clearance of the tumor infiltrate. Clinical follow-up after six months showed no recurrence.Although spontaneous regression of cutaneous Langerhans cell histiocytosis is observed, the rapid effect of photodynamic therapy after several failures of other treatment suggests that photodynamic therapy was successful. As far as we know this is the first report of photodynamic therapy for refractory skin lesions. Larger series are needed to determine whether photodynamic therapy deserves a place in the treatment of multiresistant cutaneous Langerhans cell histiocytosis.

show abstract

“…La thalidomide s'est avérée décevante dans les formes multisystémiques mais plusieurs observations font état de son efficacité dans les formes cutanéomuqueuses de la maladie, y compris périnéales et génitales [73,74]. L'utilisation de méthotrexate a également été rapportée [75].…”

Section: De Faç On Systématiqueunclassified

Histiocytose langerhansienne de l’adulte

Néel

Artifoni

Donadieu

et al. 2015

La Revue de Médecine Interne

View full text Add to dashboard Cite

Langerhans cell histiocytosis (LCH) is a rare disease characterized by the infiltration of one or more organs by Langerhans cell-like dendritic cells, most often organized in granulomas. The disease has been initially described in children. The clinical picture of LCH is highly variable. Bone, skin, pituitary gland, lung, central nervous system, lymphoid organs are the main organs involved whereas liver and intestinal tract localizations are less frequently encountered. LCH course ranges from a fulminant multisystem disease to spontaneous resolution. Several randomized controlled trials have enable pediatricians to refine the management of children with LCH. Adult LCH has some specific features and poses distinct therapeutic challenges, knowing that data on these patients are limited. Herein, we will provide an overview of current knowledge regarding adult LCH and its management. We will also discuss recent advances in the understanding of the disease, (i.e. the role of BRAF oncogene) that opens the way toward targeted therapies.

show abstract

Successful treatment of cutaneous Langerhans cell histiocytosis with low-dose methotrexate.

Abstract: Langerhans cell histiocytosis (LCH) can be a difficult therapeutic problem. We present a 40-year-old woman with a 4-year history of LCH who was successfully treated with low-dose methotrexate (20 mg weekly).

Cited by 70 publications

References 9 publications

Langerhans Cell Histiocytosis: A Clinicopathologic Review and Molecular Pathogenetic Update

Langerhans Cell Histiocytosis: A Clinicopathologic Review and Molecular Pathogenetic Update

Photodynamic therapy for multi-resistant cutaneous Langerhans cell histiocytosis

Histiocytose langerhansienne de l’adulte

Contact Info

Product

Resources

About